Drugs / MRT5201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03767270 | Dec 2019 → Jul 2022 | ornithine carbamoyltransferase deficiency | Translate Bio, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRT5201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03767270 ↗ |
| Modality | Messenger RNA (mRNA) | “Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid with lipid-based nanoparticles” NCT03767270 ↗ |
| Route | Intravenous | “administered intravenously” NCT03767270 ↗ |